Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa

• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1
• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1

Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

• https://twitter.com/i/web/status/1800870035440775350
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1

Join us later for a some very exciting pieces of translational science across a AIRDs. All these abstracts sharing one thing in common: tissue, tissue, tissue! 16:30-18:00 Room A8.2 @RheumNow #EULAR2024 https://t.co/HrHP5tmHDD

• https://twitter.com/AurelieRheumo/status/1800868919684829560/photo/1

Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024

#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew Topic: can observational study debunk RCT? This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA

• https://twitter.com/Yuz6Yusof/status/1800867028850577678/photo/1

The great debate on JAKi risk and special warnings And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew Get the popcorn ready 🍿 #EULAR2024 https://t.co/z50Ob8q0i0

• https://twitter.com/AurelieRheumo/status/1800866706077958184/photo/1

almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024

« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024

Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24

🌎 Global disparities in steroid prescribing in #SLE 💊 HCQ assoc with decreased steroid use 📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics 📍SLE poster tour 15:30 TODAY #EULAR2024 Abs #POS0013 @RheumNow https://t.co/7pL8kpeqOs

• https://twitter.com/DrMiniDey/status/1800833564180963574/photo/1

LBA0001 (2024) EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL - looking good, nice results @rheumnow #EULAR2024

LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024

RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX) 870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024

OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024

And were are on folks!! 🎙️ Delighted to join @RheumNow faculty again this year I will be covering RA and PsA topics during #EULAR2024 Don’t miss our Daily recaps live 6pm Oh and if you see me around, come and say Hi! https://t.co/TrQ9b3WeSy

• https://twitter.com/AurelieRheumo/status/1800822311647621537/photo/1